Alizarine derivatives as new dual inhibitors of the HIV‐1 reverse transcriptase‐associated DNA polymerase and RNase H activities effective also on the RNase H activity of non‐nucleoside resistant reverse transcriptases
Open accessThe DOI matches its Crossref record; 1 of the 1 references it cites were found in a registry or an index.
Abstract
HIV‐1 reverse transcriptase (RT) has two associated activities, DNA polymerase and RNase H, both essential for viral replication and validated drug targets. Although all RT inhibitors approved for therapy target DNA polymerase activity, the search for new RT inhibitors that target the RNase H function and are possibly active on RTs resistant to the known non‐nucleoside inhibitors (NNRTI) is a viable approach for anti‐HIV drug development. In this study, several alizarine derivatives were synthesized and tested for both HIV‐1 RT‐associated activities. Alizarine analogues K‐49 and KNA‐53 showed IC 50 values for both RT‐associated functions of ∼ 10 μ m. When tested on the K103N RT, both derivatives inhibited the RT‐associated functions equally, whereas when tested on the Y181C RT, KNA‐53 inhibited the RNase H function and was inactive on the polymerase function. Mechanism of action studies showed that these derivatives do not intercalate into DNA and do not chelate the divalent cofactor Mg 2+. Kinetic studies demonstrated that they are noncompetitive inhibitors, they do not bind to the RNase H active site or to the classical NNRTI binding pocket, even though efavirenz binding negatively influenced K‐49/KNA‐53 binding and vice versa. This behavior suggested that the alizarine derivatives binding site might be close to the NNRTI binding pocket. Docking experiments and molecular dynamic simulation confirmed the experimental data and the ability of these compounds to occupy a binding pocket close to the NNRTI site.
Overview
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
The claims and statistics of this paper haven’t been checked yet.
Free: it reads the open-access text and checks the first 5 claims that cite a source we can check. Create a free account to check every claim.
Self-check
Percentages, sums and reported differences re-computed from the paper’s own numbers.
The self-check needs the paper’s full text.
Citations
Cites
Hang, J. Q., Li, Y., Yang, Y., Cammack, N., Mirzadegan, T., & Klumpp, K. (2007) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2006.11.018 · Cited by 54
Cited by
Cuzzucoli Crucitti, G., Métifiot, M., Pescatori, L., Messore, A., Madia, V. N., Pupo, G., Saccoliti, F., Scipione, L., Tortorella, S., Esposito, F., et al. (2015) · Journal of Medicinal Chemistry · doi:10.1021/jm501799k · Cited by 81
Self-citationActive site and allosteric inhibitors of the ribonuclease H activity of HIV reverse transcriptase
Corona, A., Masaoka, T., Tocco, G., Tramontano, E., & Le Grice, S. F. (2013) · Future Medicinal Chemistry · doi:10.4155/fmc.13.178 · Cited by 54
Self-citationRecent progress in the research of small molecule HIV-1 RNase H inhibitors
Cao, L., Song, W., Clercq, E., Zhan, P., & Liu, X. (2014) · Current Medicinal Chemistry · doi:10.2174/0929867321666140120121158 · Cited by 34
Metadata
- Authors
- Esposito, F., Kharlamova, T., Distinto, S., Zinzula, L., Cheng, Y., Dutschman, G., Floris, G., Markt, P., Corona, A., & Tramontano, E.
- Venue
- The FEBS Journal
- Publisher
- Wiley
- Published
- 2011-03-16
- Volume
- 278
- Issue
- 9
- Pages
- 1444-1457
- ISSN
- 1742-464X (ISSN-L)
- 1742-4658
- OpenAlex
- W1491518302
- Cited by
- 35
- References
- 1
- FWCI
- 3.20
- Type
- journal article
- Language
- en
- Open access
- green
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
How to cite
Cite CoChat for the checks on this page, and the paper for its own findings.
- This page
- CoChat. (2026). Citation check: Alizarine derivatives as new dual inhibitors of the HIV‐1 reverse transcriptase‐associated DNA polymerase and RNase H activities effective also on the RNase H activity of non‐nucleoside resistant reverse transcriptases. https://app.cochat.ai/papers/10.1111/j.1742-4658.2011.08057.x
- The paper
- Esposito, F., Kharlamova, T., Distinto, S., Zinzula, L., Cheng, Y., Dutschman, G., Floris, G., Markt, P., Corona, A., & Tramontano, E. (2011). Alizarine derivatives as new dual inhibitors of the HIV‐1 reverse transcriptase‐associated DNA polymerase and RNase H activities effective also on the RNase H activity of non‐nucleoside resistant reverse transcriptases. The FEBS Journal. https://doi.org/10.1111/j.1742-4658.2011.08057.x
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.